a. Ensure that collaborations are performed pursuant to a written agreement or memorandum that is established in advance with a description of the expected deliverables. It is recognized that it may not always be practicable to establish a written agreement in advance; however, as soon as feasible the collaboration should be reduced to writing. Additionally, pursuant to University policy, the agreement or memorandum should include Commercial Health Care Company’s acknowledgement and understanding that the physician or health professional is acting solely in his/her individual capacity and not as an agent or representative of Washington University, and that Washington University assumes no liabilities or obligations under the collaboration. b. Maintain documentation of the compensation received and the services provided, including reasonable estimates of the time and effort committed to providing the services.c. Ensure that compensation is based on, and commensurate with, the provision of tangible services and not on the decision to use a specific device, implant or drug in a patient.
a. Names of companies with whom faculty member has a financial relationshipb. Basis for payments (ex: consulting, educational lectures, royalties, equity or stock options, etc)c. Range of reimbursement for most recent 12 month period
a. All financial support by industry must be reported to, and fully disclosed by, the meeting sponsor.b. Speakers must have final editorial discretion as to lecture content and materials. Faculty may not participate as a presenter or panelist in corporate Speakers Bureaus or other corporate-sponsored forums if the company controls what the faculty member says or otherwise has the final approval rights over the faculty member’s presentation materials. Company-provided content, materials and review necessary to ensure compliance with FDA regulations are acceptable, so long as the faculty member retains editorial discretion over the remainder of the information presented. Given that arrangements for these speaking engagements should be made in writing between the sponsor and the speaker, contracts or correspondence engaging Washington University faculty in such instances must include the following language: “As speaker or panelist, (speaker) will have control over his/her own comments and content, except where compliance with FDA or other regulatory agency guidelines requires speakers to adhere to content that meets the agency’s guidelines or proscriptions."c. Speakers must provide a fair and balanced assessment of therapeutic options and promote objective scientific and educational discourse.d. Speakers should make it clear that the lecture content reflects their individual views and not the views of WUSM or its affiliated teaching hospitals.e. Use of the Washington University name in non-University events sponsored by Commercial Health Care companies should be limited to identifying the speaker by his/her title and affiliation.f. Powerpoint presentations, slides, handouts, brochures, flyers, mail and email announcements of industry-sponsored lectures cannot be co-branded using Washington University symbols, logos or images.g. Presentations that provide information related to non-FDA approved uses for drug products and/or devices must clearly acknowledge the unlabeled indications or investigational nature of their proposed uses to the audience.h. Individual agreements with industry for educational lectures must be for a finite term not to exceed 5 [five] years.
About Us |
For Your Protection |
Contact Us |
© 2013 Washington University School of Medicine.